Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
said it plans to spend $2.2 billion to build a new manufacturing site in Ohio for its pharmaceutical business, becoming the latest European drugmaker to invest in the U.S. The German agricultural and pharmaceutical group said Friday that its new…
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
The German company's pharma business has been looking to expand in the U.S., betting that an enlarged presence in the world's largest drug market can help it revive sales growth after two key products went off patent.
Avalyn Pharma (NASDAQ:AVLN) Upgraded at Raymond James Financial
Avalyn Pharma (NASDAQ:AVLN - Get Free Report) was upgraded by equities researchers at Raymond James Financial to a 'moderate buy' rating in a research report issued on Friday, Zacks reports. Other research analysts also recently issued research…
Spyglass Pharma (NASDAQ:SGP) Stock Moved Down to Sell by Wall Street Zen
Spyglass Pharma (NASDAQ:SGP - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a 'hold' rating to a 'sell' rating in a note issued to investors on Saturday, Wall Street Zen reports. SGP has been the topic of a number…
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $1,257,657.38 in Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Kastelein sold 50,246 shares of the stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total transaction…
The cost of convenience: Why big pharma must choose independence over short-term profits - Ya Libnan
Photo illustration -“Investing in AI, research and pharmaceutical manufacturing today can protect tomorrow's patients from dependence and blackmail.” True innovation is not just about discovering a cure—it is about ensuring you…
Big Pharma's China deals worth billions: Chinese biotech out licensing deals to surpass $250 billion in 2026 - Ya Libnan
Novartis has signed a deal worth up to $7.8 billion, in the latest of a flurry of tie-ups between Big Pharma and Chinese biotechs. The Swiss pharma major is entering a licensing agreement with China-based Abogen Biosciences for its lead asset, an…
Cipla faces fresh FDA blow, Pune warehouse drug licences cancelled
The Maharashtra Food and Drug Administration has cancelled the drug sale and distribution licences for Cipla Pharma & Life Sciences Ltd's Pune warehouse, citing significant violations related to misbranding and storage of the Schedule H drug…
FDA cancels drug sale licence of Cipla facility in Pune
The Maharashtra Food and Drug Administration (FDA) on Friday said it has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding (C&F) warehouse at Wadki in Pune following detection of alleged…
Novartis signs $7.8 billion drug deal with Chinese startup
Novartis on Friday signed a drug licensing deal with China's Abogen Biosciences that could be worth up to $7.8 billion. Why it matters: This is the latest example of a Western pharma giant partnering with a Chinese biotech — a trend that…
Nil Gimeno snares first professional win at stage 7 of Le Tour de Langkawi to Batu Pahat
Nil Gimeno (Equipo Kern Pharma) took his first professional victory on stage 7 of Le Tour de Langkawi to Batu Pahat, as the break of four prevailed despite a charged pursuit by the sprinters teams. Gimeno, who was a frustrating fourth on stage 4…
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Eli Lilly (NYSE:LLY | LLY Price Prediction) trades at $1,184.92, which gives it a market value of about $1.057 trillion. The 24/7 Wall St. price target for Eli Lilly is $1,401.42 over the next 12 months. That means 18.27% upside and earns a…
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP
The VanEck Pharmaceutical ETF (PPH -0.07%) provides a lower-cost entry and higher yield than the Invesco Pharmaceuticals ETF (PJP -0.30%), which has shown stronger 1-year returns and more concentrated top holdings. These ETFs target the…
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
Novo Nordisk (NVO -0.21%) is looking to maintain its position in the weight-loss market and one-up its most important competitor, Eli Lilly (LLY -0.61%). To that end, the Denmark-based pharmaceutical giant has developed several promising…
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
As the global healthcare landscape shifts toward weight-loss treatments and chronic care, investors are weighing two giants. Should you invest in Novo Nordisk A/S (NVO -0.55%) or Pfizer Inc. (PFE -2.15%) today? Novo Nordisk A/S has built a dominant…
Receive a Daily briefing on Pharma Industry News
Get Started